

Brexafemme Kit can cost $450-$600 without insurance. Learn how to save with coupons, discount cards, copay assistance, and patient assistance programs.
If you've been prescribed Brexafemme Kit (Ibrexafungerp) for a vaginal yeast infection or to prevent recurrent yeast infections, you may have experienced sticker shock. Without insurance, a single treatment course of Brexafemme Kit can cost between $450 and $600. Even with insurance, copays and deductibles can leave you paying hundreds out of pocket.
While the drug is currently temporarily unavailable (as of early 2026), this guide will help you understand the full cost picture and prepare to save money when Brexafemme Kit returns to market. Whether you're uninsured, underinsured, or looking to minimize your copay, there are programs and strategies that can help.
Here's what patients have typically paid for Brexafemme Kit:
These prices make Brexafemme Kit one of the more expensive antifungal treatments on the market, especially compared to generic Fluconazole at $3–$15 per dose.
When Brexafemme Kit was commercially available, Scynexis offered a copay savings card for eligible commercially insured patients. Key details:
With the NDA now transferred to GSK, the savings program details may change when the drug returns to market. Check with GSK or your pharmacy for updated copay assistance information.
Prescription discount cards can reduce the cash price of Brexafemme Kit, though the savings may vary depending on the pharmacy:
Discount cards are free to use and don't require insurance. They can be especially helpful if your insurance doesn't cover Brexafemme Kit or if you haven't met your deductible.
If you're uninsured, underinsured, or facing financial hardship, patient assistance programs (PAPs) may provide Brexafemme Kit for free or at a significantly reduced cost:
Scynexis offered a patient assistance program for eligible patients who couldn't afford their medication. With the transfer to GSK, check these resources:
These programs typically require documentation of income and insurance status. Your doctor's office can often help with the application process.
If cost is a major concern, discuss more affordable alternatives with your doctor:
While these alternatives have different mechanisms of action and may not be as effective for resistant infections, they're worth discussing with your healthcare provider — especially if you're paying out of pocket. See our full comparison: Alternatives to Brexafemme Kit.
When Brexafemme Kit returns to market, your doctor's office may receive samples from GSK. Ask your prescriber if samples are available before filling a prescription — this could save you an entire treatment course worth of costs.
As of 2026, there is no generic version of Brexafemme (Ibrexafungerp) approved by the FDA. This means the brand-name product is the only option, and patients cannot access a lower-cost generic alternative. If and when a generic becomes available, the price could drop significantly — but that timeline is uncertain.
Brexafemme Kit is an effective but expensive treatment for vaginal yeast infections. At $450–$600 per course without insurance, finding ways to save is essential. The manufacturer copay card (as low as $30), prescription discount cards, and patient assistance programs can all help reduce your costs.
While the drug is currently temporarily unavailable, use this time to explore your insurance coverage, register for patient assistance programs, and talk to your doctor about the most cost-effective treatment plan for your situation.
For help finding Brexafemme Kit in stock when it returns, visit Medfinder. For the latest on the shortage, see: Brexafemme Kit Shortage Update.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.